Aardvark Therapeutics (NASDAQ:AARD) Insider Nelson Sun Sells 14,754 Shares

Aardvark Therapeutics, Inc. (NASDAQ:AARD) insider Nelson Sun sold 14,754 shares of Aardvark Therapeutics stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $5.00, for a total transaction of $73,770.00. Following the completion of the transaction, the insider owned 97,475 shares in the company, valued at $487,375. This trade represents a 13.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Nelson Sun also recently made the following trade(s):

• On Friday, September 11th, Nelson Sun sold 62,000 shares of Aardvark Therapeutics stock. The shares were sold at an average price of $5.18, for a total transaction of $321,160.00.

Aardvark Therapeutics Price Performance

AARD stock opened at $5.13 on Friday. The stock has a market capitalization of $112.26 million, a price-to-earnings ratio of -1.60 and a beta of 3.74. The company has a 50-day moving average of $6.29 and a two-hundred day moving average of $5.53. Aardvark Therapeutics, Inc. has a 52-week low of $3.35 and a 52-week high of $17.94.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21. Equities analysts expect that Aardvark Therapeutics, Inc. will post -3.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Aardvark Therapeutics

Several large investors have recently added to or reduced their stakes in the company. SymBiosis Capital Partners LLC bought a new stake in shares of Aardvark Therapeutics during the fourth quarter valued at approximately $6,255,000. Millennium Management LLC acquired a new position in shares of Aardvark Therapeutics in the third quarter valued at $4,248,000. BlackRock Inc. bought a new position in Aardvark Therapeutics in the second quarter worth $1,077,000. Geode Capital Management LLC lifted its position in Aardvark Therapeutics by 53.5% in the fourth quarter. Geode Capital Management LLC now owns 297,865 shares of the company’s stock worth $3,910,000 after purchasing an additional 103,830 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Aardvark Therapeutics by 20.6% during the third quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock worth $7,386,000 after buying an additional 94,744 shares in the last quarter.

Key Aardvark Therapeutics News

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: No company-specific clinical, regulatory, or financial improvement was reported in the latest updates. The absence of new adverse operating news may limit additional selling pressure.
• Neutral Sentiment: Several law firms—including Hagens Berman, Rosen Law Firm, SBS Law, Pomerantz, Faruqi & Faruqi, and Bernstein Liebhard—are soliciting investors to seek lead-plaintiff status by October 13, 2026. These announcements largely repeat the same underlying lawsuit rather than representing separate cases. Hagens Berman investor notice
• Neutral Sentiment: A reported September short-interest update showed zero shares sold short, but the figures appear incomplete or unreliable because the reported change was listed as “NaN.” It therefore provides little useful insight into trading direction.
• Negative Sentiment: The securities class action covers investors who bought Aardvark shares in or traceable to the February 2025 IPO, or who purchased securities between February 13, 2025, and May 14, 2026. The litigation alleges violations of federal securities laws by the company and certain officers and directors. Pomerantz class-action announcement
• Negative Sentiment: One investor notice alleges that IPO materials described Aardvark’s ARD-101 drug candidate as 99% restricted to the gut and reported no serious adverse events, while allegedly omitting safety risks that later led to an FDA clinical hold. These remain allegations, but the claims create potential legal costs, uncertainty, and reputational damage. AARD shareholder alert

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. B. Riley Financial reduced their price objective on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Wall Street Zen raised shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. HC Wainwright reiterated a “neutral” rating and set a $6.00 target price on shares of Aardvark Therapeutics in a research note on Monday, July 20th. BTIG Research downgraded shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Finally, Morgan Stanley reissued an “underweight” rating and issued a $3.00 price target (down from $7.00) on shares of Aardvark Therapeutics in a report on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $15.33.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.